MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
Rinaldi F, Marchesi F, Palombi F, Pelosi A, Di Pace AL, Sacconi A, Terrenato I, Annibali O, Tomarchio V, Marino M, Cantonetti M, Vaccarini S, Papa E, Moretta L, Bertoni F, Mengarelli A, Regazzo G, Rizzo MG.
Rinaldi F, et al. Among authors: di pace al.
Br J Haematol. 2021 Nov;195(3):399-404. doi: 10.1111/bjh.17734. Epub 2021 Jul 28.
Br J Haematol. 2021.
PMID: 34318932